EcoDrugPlus

Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1-Like

Ensembl ID : ENSACLG00000020057
Gene Symbol: LOC113034408
2 Cross references
198 Possible Orthologues:

Mucosal Pentraxin-Like

Ensembl ID : ENSACLG00000006493
Gene Symbol: LOC113032229
2 Cross references
406 Possible Orthologues:

Mucosal Pentraxin-Like

Ensembl ID : ENSACLG00000006484
Gene Symbol: LOC113032227
2 Cross references
357 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSACLG00000027012
Gene Symbol: LOC113027482
2 Cross references
186 Possible Orthologues:

Muscarinic Acetylcholine Receptor M4-Like

Ensembl ID : ENSACLG00000015764
Gene Symbol: LOC113016038
2 Cross references
184 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSACLG00000001973
Gene Symbol: LOC113012423
3 Cross references
194 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSACLG00000016943
Gene Symbol: NPR3
3 Cross references
210 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSACLG00000027910
Gene Symbol: LOC113025559
3 Cross references
195 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSACLG00000019952
Gene Symbol: LOC113020561
3 Cross references
194 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSACLG00000020622
Gene Symbol: LOC113024255
3 Cross references
201 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSACLG00000014046
Gene Symbol: LOC113019138
3 Cross references
208 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSACLG00000027372
Gene Symbol: NPY2R
3 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).